Something has shifted in how pharmaceutical companies talk about sustainability. A few years ago, net zero pledges, Science Based Targets, and ESG commitments were front and centre. Today, the language is quieter. Timelines are being stretched. Scopes are being narrowed. In some cases, the conversation has almost disappeared.
The honest question is why. From what I see across the sector, and from what is now appearing in regulatory and legal action, the answer is not one thing. It is a collision of pressures, some external and some self-inflicted.
US headwinds are real
The political backlash against ESG in the United States is not abstract. Since 2023, ESG has become a contested term, particularly for companies exposed to state funds and investors who now openly challenge ESG mandates. Several pharma companies have responded by turning down the public volume, even where internal work continues.
There is also a commercial reality. High interest rates, pressure on quarterly performance, and tight pricing in regulated medicines markets make long payback sustainability investments harder to approve. In recent industry surveys, many biopharma firms report missing revenue or margin targets. When sustainability targets start to look out of reach, some organisations choose softer language rather than publicly owning the miss.
That is understandable, even if it is not ideal leadership.
COVID also reshaped boardroom priorities. Supply security and resilience rightly took precedence. Avoiding API shortages and logistics disruption mattered more than decarbonisation initiatives that might introduce supplier or process risk. In that context, some caution was sensible.
Layered on top of this is the rapid growth in US on-shoring. New manufacturing capacity is being planned and delivered at speed, driven by geopolitical risk and domestic incentives. That pace matters, because it creates both opportunity and risk.
Europe is moving the other way
While some companies are stepping back from public sustainability claims in response to US pressure, Europe and Canada are tightening the opposite way.
The EU Directive on Empowering Consumers for the Green Transition, approved in January 2024, has fundamentally raised the bar. Environmental claims now require
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cleanroom Technology.
Subscribe now Already a subscriber? Sign in here.
